SCHEMBL506500

SCHEMBL506500

CC(CO[Si](C(C)C)(C(C)C)C(C)C)n1cc(Br)ccc1=O

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.32
POLB P06746 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
AHR P35869 1/20 0.32
NPC1 O15118 2/20 0.31
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31
ALDH1A1 P00352 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
RXFP1 Q9HBX9 2/20 0.31
LMNA P02545 1/20 0.31
MAPK1 P28482 1/20 0.30
BMPR1B O00238 1/20 0.30
BMPR1A P36894 1/20 0.30
TGFBR1 P36897 1/20 0.30
ACVRL1 P37023 1/20 0.30
ACVR1 Q04771 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28645389 0.81 ALDH1A1 (0.38) KDM4EPOLBCTDSP1L3MBTL1AHR
SCHEMBL22655366 0.76 BMPR1B (0.39) KDM4EAHRNPC1GAARAB9A
SCHEMBL506044 0.75 ADORA2A (0.38) ALDH1A1LMNABMPR1BBMPR1ATGFBR1
SCHEMBL506398 0.74 PTGS2 (0.35) KDM4EPOLBL3MBTL1AHRRXFP1
SCHEMBL505992 0.74 PTGS2 (0.35) KDM4EPOLBCTDSP1L3MBTL1AHR
SCHEMBL505959 0.74 LPL (0.34)
SCHEMBL22655338 0.67 PTGS2 (0.31) NPC1GAARAB9ASMN1; SMN2
SCHEMBL505945 0.66 FPR2 (0.46) KDM4EPOLBL3MBTL1NPC1GAA
SCHEMBL22552042 0.65 ALDH1A1 (0.33) ALDH1A1RXFP1LMNA
SCHEMBL506213 0.65 PTGS2 (0.45) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 US disclosed
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 US disclosed
EP-2569313-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed
WO-2011143426-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 KDM4E 1834/4885POLB 793/4885CTDSP1 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.